Marya Postner

Marya represents public and private life sciences companies in an eclectic range of complex transactions – including collaborations, license agreements, options to license or purchase, territory-specific licenses, joint venture and other profit-sharing arrangements, co-promotion relationships, and manufacturing and supply agreements. She counsels clients with respect to the structuring and negotiation of agreements designed to maximize the value of the company's products and technology assets. She is highly experienced in handling strategic alliances between biotechnology and pharmaceutical companies in areas as diverse as collaborative research and the development and marketing of late-stage pharmaceutical products.

Marya has a PhD in molecular biology from Princeton University. She was the head of Cooley’s global life sciences corporate partnering and licensing practice group from 2020 through 2024, and she previously practiced in the firm's patent counseling and prosecution group. She combines her resulting knowledge of scientific and intellectual property matters with a deep understanding of the life sciences industry to help her clients devise creative solutions to issues that arise during the negotiation or implementation of their most important collaborative relationships.

Marya’s recent representative transactions include:

• Unnatural Products’ licensing agreement with Novartis to develop macrocyclic peptide therapeutics
• 4D Molecular Therapeutics’ licensing agreement with Otsuka for ophthalmic gene therapy drug candidate 4D-150, which is an anti-vascular endothelial growth factor agent
• Athira Pharma’s exclusive license to the Phase 3 development program for Lasofoxifene to treat metastatic breast cancer candidate, as well as a financing for up to $236 million
• Jazz Pharmaceuticals’ exclusive licensing agreement with Saniona to develop and commercialize SAN2355
• Neurocrine’s $880 million agreement with TransThera to develop an immunology target
• Unnatural Products and argenx’s $1.5 billion agreement to develop macrocyclic peptides to target traditionally “undruggable” diseases
• Wisconsin Alumni Research Foundation’s agreement with SK Biopharmaceuticals to license a radiopharmaceutical candidate
• Sangamo Therapeutics and Astellas’ capsid license agreement to deliver genomic medicines for neurological diseases
• Allorion Therapeutics’ exclusive option and global licensing agreement with AstraZeneca
• Chimagen Biosciences’ sale of CMG1A46 to global biopharma company GSK
• Cytokinetics and Bayer’s exclusive licensing collaboration for aficamten in Japan
• Jazz Pharmaceuticals’ definitive agreement with Redx Pharma to acquire global rights to its KRAS inhibitor program
• Unnatural Products and Merck & Co.’s $220 million macrocyclic peptide agreement
• Jazz Pharmaceuticals and Zymeworks’ partnership for Zanidatamab
• Jazz Pharmaceuticals’ exclusive global licensing and collaboration agreement with Autifony on two ion channel targets for neurological disorders
• SCYNEXIS’ exclusive licensing agreement with GSK for Brexafemme
• Senti Bio’s strategic collaboration with Celest Therapeutics for clinical development of SENTI-301A in China
• Jazz Pharmaceuticals and Werewolf Therapeutics’ exclusive global licensing and collaboration agreement to develop WTX-613, a differentiated, conditionally-activated IFNα INDUKINE™ molecule
• Jazz Pharmaceuticals and Sumitomo Pharma’s exclusive licensing agreement to develop and commercialize DSP-0187, a potent, highly selective oral orexin-2 receptor agonist
• Poseida Therapeutics’ strategic collaboration and licensing agreement with Roche
• Surrozen’s strategic partnership with Boehringer Ingelheim to develop Wnt Agonist SZN-413 for people with retinal diseases
• NGM Bio and Merck’s collaboration on retinal, cardiovascular and metabolic diseases
• Prothena’s agreement to sell its ATTR amyloidosis program to Novo Nordisk
• Senti Bio and BlueRock Therapeutics’ collaboration to develop gene circuit-engineered cell therapies for regenerative medicine
• Senti Bio’s collaboration with Spark Therapeutics to bolster an industry-leading gene therapy research platform
• Sangamo Therapeutics’ agreement with Biogen for the development and commercialization of gene regulation therapies for Alzheimer’s, Parkinson’s and other neurological diseases
• Sangamo Therapeutics’ global collaboration agreement with Novartis to develop and commercialize gene regulation therapies